Imaging dopamine transmission parameters in cannabis dependence

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 52, Issue , 2014, Pages 28-32

  Ghazzaoui, Rassil ^a   Abi Dargham, Anissa ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cannabis; Dependence; Dopamine; Imaging; PET

Indexed keywords

AMPHETAMINE; CANNABINOID 1 RECEPTOR; CANNABIS; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DRONABINOL; CANNABINOID; DOPAMINE;

ARTICLE; BRAIN REGION; CANNABIS ADDICTION; CANNABIS USE; CORPUS STRIATUM; CORRELATIONAL STUDY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; HUMAN; ONSET AGE; POSITRON EMISSION TOMOGRAPHY; SUBSTANCE ABUSE; ANIMAL; DRUG EFFECTS; METABOLISM; NEUROIMAGING; PATHOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; CANNABINOIDS; CORPUS STRIATUM; DOPAMINE; HUMANS; MARIJUANA ABUSE; NEUROIMAGING; SYNAPTIC TRANSMISSION;

EID: 84899656185     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.10.013     Document Type: Article

References (41)

1. Abi-Dargham A., Kegeles L.S., Martinez D., Innis R.B., Laruelle M. Dopamine mediation of positive reinforcing effects of amphetamine in stimulant naive healthy volunteers: results from a large cohort. Eur Neuropsychopharmacol 2003, 13:459-468.
2. Albrecht D.S., Skosnik P.D., Vollmer J.M., Brumbaugh M.S., Perry K.M., Mock B.H., et al. Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users. Drug Alcohol Depend 2013, 128:52-57.
3. Barkus E., Morrison P.D., Vuletic D., Dickson J.C., Ell P.J., Pilowsky L.S., et al. Does intravenous Delta9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol 2011, 25:1462-1468.
4. Bloomfield M.A., Morgan C.J., Egerton A., Kapur S., Curran H.V., Howes O.D. Dopaminergic Function in Cannabis Users and Its Relationship to Cannabis-Induced Psychotic Symptoms 2013, Biol, Psychiatry.
5. Bossong M.G., Van Berckel B.N., Boellaard R., Zuurman L., Schuit R.C., Windhorst A.D., et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009, 34:759-766.
6. Budney A.J., Moore B.A., Vandrey R.G., Hughes J.R. The time course and significance of cannabis withdrawal. J Abnorm Psychol 2003, 112:393-402.
7. Chen J.P., Paredes W., Li J., Smith D., Lowinson J., Gardner E.L. Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl) 1990, 102:156-162.
8. Degenhardt L., Hall W., Lynskey M. Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. Addiction 2001, 96:1603-1614.
9. Fadda P., Scherma M., Spano M.S., Salis P., Melis V., Fattore L., et al. Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport 2006, 17:1629-1632.
10. French E.D. delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 1997, 226:159-162.
11. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003, 83:1017-1066.
12. Gaoni Y., R.M Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964, 86:1646-1647.
13. Gessa G.L., Melis M., Muntoni A.L., Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 1998, 341:39-44.
14. Glass M., Felder C.C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 1997, 17:5327-5333.
15. Henquet C., Di Forti M., Morrison P., Kuepper R., Murray R.M. Gene-environment interplay between cannabis and psychosis. Schizophr Bull 2008, 34:1111-1121.
16. Hirvonen J., Goodwin R.S., Li C.T., Terry G.E., Zoghbi S.S., Morse C., et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 2012, 17(6):642-649. (Epub 2011 Jul 12). 10.1038/mp.2011.82.
17. Johnston L.D., O'Malley P.M., Bachman J.G., Je S. The monitoring the future national survey results on adolescent drug use: overview of key findings, 2009 2010, (Bethesda, MD). N.I.O.D. Abuse (Ed.).
18. Kadden R.M., Litt M.D., Kabela-Cormier E., Petry N.M. Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav 2007, 32:1220-1236.
19. Leroy C., Karila L., Martinot J.L., Lukasiewicz M., Duchesnay E., Comtat C., et al. Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study. Addict Biol 2012, 17:981-990.
20. Martinez D., Narendran R. Imaging neurotransmitter release by drugs of abuse. Curr Top Behav Neurosci 2010, 3:219-245.
21. Martinez D., Gil R., Slifstein M., Hwang D.R., Huang Y., Perez A., et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 2005, 58:779-786.
22. Martinez D., Narendran R., Foltin R.W., Slifstein M., Hwang D.R., Broft A., et al. Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 2007, 164:622-629.
23. Martinez D., Carpenter K.M., Liu F., Slifstein M., Broft A., Friedman A.C., et al. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am J Psychiatry 2011, 168:634-641.
24. Mizrahi R., Suridjan I., Kenk M., George T.P., Wilson A., Houle S., et al. Dopamine response to psychosocial stress in chronic cannabis users: a PET study with [(11)C]-(+)-PHNO. Neuropsychopharmacology 2013, 38:673-682.
25. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
26. Ng Cheong Ton J.M., Gerhardt G.A., Friedemann M., Etgen A.M., Rose G.M., Sharpless N.S., et al. The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study. Brain Res 1988, 451:59-68.
27. NIDA Marijuana: facts parents need to know 2011 rev, SERVICES, U. S. D. O. H. A. H. (Ed.).
28. Pistis M., Perra S., Pillolla G., Melis M., Muntoni A.L., Gessa G.L. Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry 2004, 56:86-94.
29. Pope H.G., Gruber A.J., Hudson J.I., Huestis M.A., Yurgelun-Todd D. Cognitive measures in long-term cannabis users. J Clin Pharmacol 2002, 42:41S-47S.
30. SAMHSA Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings 2010, NSDUH, Rockville, MD. STUDIES, O. O. A. (Ed.).
31. Schweinsburg A.D., Brown S.A., Tapert S.F. The influence of marijuana use on neurocognitive functioning in adolescents. Curr Drug Abuse Rev 2008, 1:99-111.
32. Sevy S., Smith G.S., Ma Y., Dhawan V., Chaly T., Kingsley P.B., et al. Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. Psychopharmacology (Berl) 2008, 197:549-556.
33. Stokes P.R., Mehta M.A., Curran H.V., Breen G., Grasby P.M. Can recreational doses of THC produce significant dopamine release in the human striatum?. Neuroimage 2009, 48:186-190.
34. Stokes P.R., Egerton A., Watson B., Reid A., Lappin J., Howes O.D., et al. History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. J Psychopharmacol 2012, 26(1):144-149. (Epub 2011 Sep 2). 10.1177/0269881111414090.
35. Troisi A., Pasini A., Saracco M., Spalletta G. Psychiatric symptoms in male cannabis users not using other illicit drugs. Addiction 1998, 93:487-492.
36. Urban N.B., Slifstein M., Thompson J.L., Xu X., Girgis R.R., Raheja S., et al. Dopamine release in chronic cannabis users: a [11c]raclopride positron emission tomography study. Biol Psychiatry 2012, 71:677-683.
37. Volkow N.D., Hitzemann R., Wang G.J., Fowler J.S., Wolf A.P., Dewey S.L., et al. Long-term frontal brain metabolic changes in cocaine abusers. Synapse 1992, 11:184-190.
38. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Gatley S.J., Hitzemann R., et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997, 386:830-833.
39. Voruganti L.N., Slomka P., Zabel P., Mattar A., Awad A.G. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res 2001, 107:173-177.
40. Wang G.J., Smith L., Volkow N.D., Telang F., Logan J., Tomasi D., et al. Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 2012, 17(9):918-925. (Epub 2011 Jul 12). 10.1038/mp.2011.86.
41. Yucel M., Solowij N., Respondek C., Whittle S., Fornito A., Pantelis C., et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 2008, 65:694-701.